Beam Therapeutics (BEAM) Return on Capital Employed: 2020-2025
Historic Return on Capital Employed for Beam Therapeutics (BEAM) over the last 6 years, with Sep 2025 value amounting to -0.40%.
- Beam Therapeutics' Return on Capital Employed fell 23.00% to -0.40% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.40%, marking a year-over-year decrease of 23.00%. This contributed to the annual value of -0.38% for FY2024, which is 23.00% down from last year.
- Latest data reveals that Beam Therapeutics reported Return on Capital Employed of -0.40% as of Q3 2025, which was down 12.28% from -0.36% recorded in Q2 2025.
- In the past 5 years, Beam Therapeutics' Return on Capital Employed registered a high of -0.15% during Q1 2024, and its lowest value of -0.65% during Q1 2021.
- In the last 3 years, Beam Therapeutics' Return on Capital Employed had a median value of -0.34% in 2023 and averaged -0.29%.
- Per our database at Business Quant, Beam Therapeutics' Return on Capital Employed surged by 43bps in 2022 and then declined by 28bps in 2024.
- Quarterly analysis of 5 years shows Beam Therapeutics' Return on Capital Employed stood at -0.36% in 2021, then grew by 5bps to -0.30% in 2022, then increased by 15bps to -0.15% in 2023, then decreased by 28bps to -0.43% in 2024, then decreased by 23bps to -0.40% in 2025.
- Its Return on Capital Employed stands at -0.40% for Q3 2025, versus -0.36% for Q2 2025 and -0.38% for Q1 2025.